Adding platinum to neoadjuvant chemotherapy has been proved to increase the pCR rate in TNBC patients and the accompanying adverse effect is tolerable and manageable although the benefit of overall survival has not been well-established.
This lecture aims to present the efficacy and safety of various neoadjuvant regimens for patients diagnosed with early stage or locally advanced triple-negative breast cancer (TNBC).贊助廠商
Administration of docetaxel in a weekly schedule may offer similar efficacy, with a more favorable toxicity profile, compared to a three-weekly schedule in patients with breast cancer.
This presentation will revisit Docetaxel schedule in early breast cancer & metastatic breast cancer.贊助廠商
對於 HR+/HER2- MBC 的病人，不管是內生性或經過內分泌藥物治療後，所產生的賀爾蒙抗性是無法避免的，如何選擇下一階段治療的化療藥物，這將是當務之急…贊助廠商
De-escalating anthracycline is gaining popularity for breast cancer patients. This lecture aims to present the non-inferiority of an anthracycline-free regimen to the standard anthracycline- based regimen for operable patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer and identify patients who are suitable for anthracycline-free regimen.贊助廠商 賽諾菲股份有限公司